Evidence map›Paper›PMID 41126293›Full record

SynthesisHuman genomics2025

The role of ABCB1 and CES1 genotypes on the efficacy and safety of dabigatran: a systematic review and meta-analysis.

Weam Aldiban, Nada G Hamam, Nereen A Almosilhy, Kholoud Elsamman, Mohamed Wagdy, Doaa Mashaly, Suhel F Batarseh, Youssef El-Sherif, Basma Badrawy Khalefa, Zina Otmani

Abstract readSystematic ReviewMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Human genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Weam AldibanFaculty of Pharmacy, International University for Science and Technology, Ghabagheb, Daraa, Syrian Arab Republic. weam.aldiban@iust.edu.sy.
Nada G HamamFaculty of Medicine, Kasr Al-Ainy, Cairo University, Cairo, Egypt.
Nereen A AlmosilhyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.
Kholoud ElsammanBiochemistry and Nutrition Department, Faculty of Women for Science, Ain Shams University, Cairo, 11566, Egypt.
Mohamed WagdyFaculty of Medicine, Modern University for Technology and Information, Cairo, Egypt.
Doaa MashalyFaculty of Medicine, October 6 University, Giza, Egypt.
Suhel F BatarsehFaculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
Youssef El-SherifCollege of Biotechnology, Misr University for Science and Technology, P. Box 77, Giza, Egypt.
Basma Badrawy KhalefaFaculty of Medicine, Ain Shams University, Cairo, Egypt.
Zina OtmaniFaculty of Medicine, Mouloud Mammeri University, Tizi Ouzou, Algeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDabigatran is a direct oral anticoagulant associated with a high incidence of gastrointestinal bleeding, which presents a significant clinical concern. Genetic polymorphisms in the enzymes responsible for drug absorption (ABCB1) and activation (CES1) may influence dabigatran's pharmacokinetics, potentially altering drug concentration and therapeutic response. The current systematic review and meta-analysis aim to identify genetic variants correlated with dabigatran exposure and evaluate their importance.

methodsWe systematically searched PubMed, Web of Science, Scopus, Cochrane Library, and Embase to identify studies on dabigatran pharmacogenomics. The review included observational and clinical studies that met eligibility criteria. RevMan 5.4 was used to conduct the meta-analysis. Quality assessment was done using ROB 2.0 and NOS tools.

resultsOut of 1336 records retrieved, 1008 were screened, resulting in 16 studies included in the systematic review and 9 in the meta-analysis. Data from 3834 participants (61.8% males) were reviewed. For the ABCB1 polymorphism rs4148738, both CT and TT genotypes decreased C

conclusionABCB1 rs4148738 T allele reduced dabigatran trough levels, while CES1 rs8192935 GG increased peak levels. CES1 rs2244613 TT raised both peak and trough levels, and its T allele was linked to higher bleeding risk. No consistent associations were found for other variants. These findings highlight CES1 rs2244613 as a key contributor to variability in dabigatran response, warranting further large-scale studies to confirm its role in personalized anticoagulation therapy.

Indexed as

ATP Binding Cassette Transporter, Subfamily BDabigatranCarboxylic Ester HydrolasesGenotypeHumansPolymorphism, Single NucleotideABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BCarboxylic Ester HydrolasesCES1 protein, humanDabigatranABCB1CES1DabigatranDirect oral anticoagulantsPharmacogeneticsPolymorphisms

Identifiers

PMID41126293
PMCPMC12542493

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.